BR0016547A - Composição para a modulação e inibição da permeabilidade vascular (vp) - Google Patents

Composição para a modulação e inibição da permeabilidade vascular (vp)

Info

Publication number
BR0016547A
BR0016547A BR0016547-6A BR0016547A BR0016547A BR 0016547 A BR0016547 A BR 0016547A BR 0016547 A BR0016547 A BR 0016547A BR 0016547 A BR0016547 A BR 0016547A
Authority
BR
Brazil
Prior art keywords
protein
src
yes
modified
vascular permeability
Prior art date
Application number
BR0016547-6A
Other languages
English (en)
Inventor
David A Cheresh
Brian Eliceiri
Robert Paul
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/470,881 external-priority patent/US6685938B1/en
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR0016547A publication Critical patent/BR0016547A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Environmental Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO PARA A MODULAçãO E INIBIçãO PERMEABILIDADE VASCULAR (VP)". A presente invenção descreve métodos para a modulação da permeabilidade vascular (VP) em tecidos usando proteína Src ou Src modificada, proteína Yes ou Yes modificada, inibidores da proteína tirosina quinase da família Src, e ácidos nucléicos capazes de expressão de proteína Src ou Src modificada, proteína Yes ou Yes modificada, inibidores da proteína tirosina quinase da família Src, ou misturas destas. A invenção também descreve métodos para a inibição da VP usando uma proteína Src ou Yes inativa ou uma mistura destas, ou proteína CSK ou proteína CSK modificada, ou ácidos nucléicos que as codifiquem, ou pelo uso de inibidores químicos da tirosina quinase da família Src tais como PP1, PP2, PD173955, AGL1872, PD162531, Radicicol R2146, e Geldanamicina, ou para a potencialização da VP usando uma proteína Src ou Yes ativa, ou uma mistura destas, ou ácidos nucléicos que as codifiquem. Com posições e artigos de manufatura relacionados também são revelados.
BR0016547-6A 1999-12-22 2000-12-22 Composição para a modulação e inibição da permeabilidade vascular (vp) BR0016547A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/470,881 US6685938B1 (en) 1998-05-29 1999-12-22 Methods and compositions useful for modulation of angiogenesis and vascular permeability using SRC or Yes tyrosine kinases
US53824800A 2000-03-29 2000-03-29
PCT/US2000/035396 WO2001045751A1 (en) 1999-12-22 2000-12-22 Angiogenesis and vascular permeability modulators and inhibitors

Publications (1)

Publication Number Publication Date
BR0016547A true BR0016547A (pt) 2002-10-29

Family

ID=27043259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016547-6A BR0016547A (pt) 1999-12-22 2000-12-22 Composição para a modulação e inibição da permeabilidade vascular (vp)

Country Status (19)

Country Link
EP (2) EP1250155B1 (pt)
JP (1) JP2003518077A (pt)
KR (1) KR100813818B1 (pt)
CN (1) CN1434727A (pt)
AT (2) ATE392215T1 (pt)
AU (1) AU781444B2 (pt)
BR (1) BR0016547A (pt)
CA (1) CA2395136A1 (pt)
CZ (1) CZ304320B6 (pt)
DE (1) DE60038631T2 (pt)
DK (2) DK1905457T3 (pt)
ES (2) ES2303514T3 (pt)
HU (1) HU229628B1 (pt)
NO (1) NO20023036L (pt)
PL (1) PL356815A1 (pt)
PT (2) PT1250155E (pt)
RU (1) RU2271216C2 (pt)
SK (1) SK287575B6 (pt)
WO (1) WO2001045751A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
ATE328888T1 (de) 2000-08-25 2006-06-15 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
EP1485042A1 (en) * 2002-03-18 2004-12-15 Medtronic AVE Inc. Medical devices for delivering anti-proliferative compositions to anatomical sites at risk of restenosis
CN1681525A (zh) * 2002-07-12 2005-10-12 曹义海 一种抑制血管渗漏和组织水肿的方法
EP1413887A1 (en) * 2002-10-22 2004-04-28 Aventis Pharma S.A. Inhibitors of Src kinase for use in Alzheimer's disease
AU2003295268A1 (en) * 2002-12-19 2004-07-14 To-Bbb Holding B.V. Nucleic acids involved in blood-brain barrier control
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
JP5520433B2 (ja) * 2004-01-21 2014-06-11 エモリー ユニバーシティー 病原体感染を処置するためのチロシンキナーゼインヒビターの組成物および使用
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
EP2463295A1 (en) * 2006-05-22 2012-06-13 The Regents of The University of California Compositions and methods for the delivery of oxygen
DE602006004196D1 (de) * 2006-06-01 2009-01-22 Cellzome Ag Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
KR101293278B1 (ko) * 2009-10-29 2013-08-09 주식회사 한독 신규 혈관누출 차단제
RU2419418C1 (ru) * 2009-11-16 2011-05-27 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Состав для удаления содержимого из атеросклеротических отложений в артериях человека
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US10293023B2 (en) 2013-03-15 2019-05-21 Children's Medical Center Corporation Method of altering vascular permeability and uses thereof
CN105311645B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 胚胎fyn相关底物efs在防治肠道病毒71型感染中的应用
CN105288654B (zh) * 2015-01-23 2018-11-30 中国人民解放军第二军医大学 蛋白酪氨酸激酶fyn癌基因在防治肠道病毒71型感染中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
ATE180276T1 (de) * 1990-01-26 1999-06-15 Washington Res Found Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
GB9417366D0 (en) * 1994-08-26 1994-10-19 Prolifix Ltd Cell cycle regulated repressor and DNA element
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
CN1278724A (zh) * 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
CN1304567C (zh) 1998-05-29 2007-03-14 斯克里普斯研究学院 使用酪氨酸激酶src调制血管生成的方法和组合物
CN1342077A (zh) * 1998-11-06 2002-03-27 诺尔股份公司 抑制血管渗透性过高的形成

Also Published As

Publication number Publication date
EP1905457B1 (en) 2012-04-18
HUP0203957A3 (en) 2005-07-28
CZ304320B6 (cs) 2014-03-05
JP2003518077A (ja) 2003-06-03
AU2740001A (en) 2001-07-03
ES2303514T3 (es) 2008-08-16
NO20023036L (no) 2002-07-22
KR20020063259A (ko) 2002-08-01
PT1250155E (pt) 2008-06-06
ES2383763T3 (es) 2012-06-26
SK8492002A3 (en) 2002-11-06
ATE392215T1 (de) 2008-05-15
SK287575B6 (sk) 2011-03-04
ATE553782T1 (de) 2012-05-15
NO20023036D0 (no) 2002-06-21
EP1250155B1 (en) 2008-04-16
DE60038631T2 (de) 2009-06-10
DE60038631D1 (de) 2008-05-29
RU2271216C2 (ru) 2006-03-10
DK1250155T3 (da) 2008-08-25
PT1905457E (pt) 2012-05-25
EP1250155A4 (en) 2003-08-20
HUP0203957A2 (hu) 2003-03-28
RU2002119399A (ru) 2004-02-27
AU781444B2 (en) 2005-05-26
DK1905457T3 (da) 2012-05-29
CA2395136A1 (en) 2001-06-28
EP1905457A1 (en) 2008-04-02
HU229628B1 (en) 2014-03-28
CN1434727A (zh) 2003-08-06
KR100813818B1 (ko) 2008-03-17
EP1250155A1 (en) 2002-10-23
WO2001045751A1 (en) 2001-06-28
PL356815A1 (en) 2004-07-12

Similar Documents

Publication Publication Date Title
BR0008365A (pt) 2-amino-6-anilino-purinas e o seu uso comomedicamento
ATE553782T1 (de) Pharmazeutische zusammensetzungen enthaltend src und / oder yes und deren verwendung
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
NO20002121L (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
ATE256131T1 (de) Calanolide zur hemmung von btk
TR199900048T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE213944T1 (de) Verwendung von immunomodulatoren
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
BRPI0416777A (pt) composto de piridinil metanona substituìdos por amino úteis no tratamento de disturbios da quinase
ES2185154T3 (es) Metodo de uso de inhibidores de la ciclooxigenasa-2 en el tratamiento y prevencion de la demencia.
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister
WO2003049691A3 (en) Antisense modulation of pctaire protein kinase 1 expression
BR0302183A (pt) Composto, composição farmacêutica e uso de um composto
ECSP003846A (es) Pirroles sustituidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 24 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.